RIGL

Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company. It discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases.

Rigel Pharmaceuticals, Inc. (RIGL) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B (3.3) C (2.3) B (3.4) A- (3.9) C+ (2.6) B- (3.1)
2026-11-07 B (3.3) C (2.3) A- (3.9) B+ (3.8) C+ (2.7) B (3.2)
2026-10-31 B (3.3) C- (1.9) B (3.4) A (4.3) C+ (2.7) B- (3.1)
2026-10-24 B (3.3) C- (1.9) B (3.5) A- (4.1) C+ (2.6) B- (3.1)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe